drugset / Trial / NCT05239533
Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney Cancer
RandomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to see if the combination of 177Lu-girentuximab and nivolumab is a safe and effective treatment for advanced clear cell renal cell carcinoma/ccRCC that has the CAIX protein.
Timeline
- Start
- 2022-02-16
- Primary completion
- 2027-03
- Completion
- 2027-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 177Lu-labeled-girentuximab | Monoclonal antibody | 1353 mbq | — |
| Subject | 177Lu-labeled-girentuximab | Monoclonal antibody | 1804 mbq | — |
| Subject | 177Lu-labeled-girentuximab | Monoclonal antibody | 2405 mbq | — |
| Subject | Nivolumab | Monoclonal antibody | 240 mg | — |